What’s the Syrian economical future ?

Large-scale destructions of infrastructure, emigration and continued (albeit somewhat subsiding) violence continue to weigh on Syria's economic conditions. Although we expect a return to modest growth in 2019, we highlight that Syrian nominal GDP will remain far below pre-civil war levels for many years. Before 2011, the performance of the Syrian economy had been relatively [...]

By |2019-03-15T11:46:50+00:00March 15th, 2019|Non classé|0 Comments

India: Near-Term Rupee Strength To Fade

Short-Term Outlook (three-to-six months) The Indian rupee has appreciated by 3.9% since  September 2018 forecast. This is on the back of improving terms of trade following a sharp drop in global oil prices. The rupee's average of INR68.40/USD in 2018 is largely in line with our INR68.50/USD average forecast for the year. We forecast the rupee to average  [...]

By |2019-03-04T12:03:35+00:00March 4th, 2019|Non classé|0 Comments

Genentech To Acquire Jecure Therapeutics. Is any place for newcomers in oncology field ?

Jecure Therapeutics, a biotechnology company with novel drug discovery programmes targeting serious inflammatory diseases, has entered into a definitive agreement by which it will be acquired by Genentech (Roche). With this acquisition, Genentech will obtain full rights to Jecure's entire preclinical portfolio of nucleotide-binding oligomerization (NOD)-like receptor family pyrin domain containing protein 3 (NLRP3) inhibitors. NLRP3 is [...]

By |2018-12-07T13:25:16+00:00December 7th, 2018|Non classé|0 Comments

Is a revolution ongoing in the German pharmaceutical market ?

Is a revolution ongoing in the German pharmaceutical market ? AMNOG, New therapies, price cute, biosimilars, and other key parameters are currently changing the german key roots. #germany #amnog #biosimilars #innovation

By |2018-11-21T09:31:03+00:00November 21st, 2018|Non classé|0 Comments

Looking for development, Alexion continues external growth and completes Syntimmune acquisition

Alexion Pharmaceuticals has successfully completed its acquisition of a clinical-stage biotechnology company, Syntimmune,. The acquisition provides to Alexion a growing pipeline with the addition of clinical-stage SYNT001, a humanised monoclonal antibody that inhibits the interaction of neonatal Fc receptor (FcRn) with Immunoglobulin G (IgG) and IgG immune complexes with the potential to treat a number of rare [...]

By |2018-11-15T08:45:35+00:00November 15th, 2018|Non classé|0 Comments

Gene therapies, body hacking, the new treatment paradigm ?

Infectious diseases pose a serious threat to health and many are still without effective treatments. Some such as human papillomavirus have the potential to also lead to the development of cancers within infected hosts. Research into treatments for infectious diseases in the past 50 years has declined with the rate of approvals for infectious disease drugs [...]

By |2018-11-14T22:13:12+00:00November 14th, 2018|Non classé|0 Comments

The end of the economic German dream ?

Germany’s economic growth may have lost momentum in Q3  on the back of disappointing developments of the foreign trade. According to preliminary estimates, the domestic output contracted for the first time since Q115 on a quarterly basis, shrinking by 0.2% q-o-q. Real GDP is likely to have expanded by 1.1% on a yearly basis. The breakdown [...]

By |2018-11-14T21:52:09+00:00November 14th, 2018|Non classé|0 Comments

Johnson & Johnson’s oncology revenues will suffer from loss of Zytiga patent protection, what strategy for the pharmaceutical giant?

Johnson & Johnson reported that the US District Court, District of New Jersey has issued a ruling invalidating all asserted claims of US Patent No. 8,822,438 for Zytiga (abiraterone acetate). The Court held that the patent claims would be infringed if the patent were valid. The patent infringement case was filed against several companies who [...]

By |2018-11-13T10:41:05+00:00November 13th, 2018|Non classé|0 Comments